Qiagen N.V. (NASDAQ:QGEN) Stock Rating Reaffirmed by Bank of America Corporation
Qiagen N.V. (NASDAQ:QGEN)‘s stock had its “neutral” rating reiterated by analysts at Bank of America Corporation in a note issued to investors on Friday. They presently have a $36.00 target price on the stock, up from their previous target price of $33.00. Bank of America Corporation’s price target suggests a potential upside of 4.20% from the stock’s previous close.
A number of other equities analysts have also weighed in on the company. TheStreet lowered Qiagen N.V. from a “b-” rating to a “c” rating in a research report on Monday, April 24th. Zacks Investment Research lowered Qiagen N.V. from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Qiagen N.V. in a research report on Tuesday, May 2nd. Barclays PLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Qiagen N.V. in a research report on Monday, May 15th. Finally, Commerzbank Ag reiterated a “buy” rating on shares of Qiagen N.V. in a report on Monday, May 15th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $31.72.
Qiagen N.V. (NASDAQ:QGEN) opened at 34.55 on Friday. The company has a 50 day moving average of $34.06 and a 200 day moving average of $30.78. Qiagen N.V. has a 1-year low of $23.72 and a 1-year high of $35.26. The company has a market capitalization of $7.87 billion, a PE ratio of 95.97 and a beta of 1.15.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/07/21/qiagen-n-v-nasdaqqgen-stock-rating-reaffirmed-by-bank-of-america-corporation.html.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. FNY Managed Accounts LLC acquired a new position in shares of Qiagen N.V. during the first quarter worth about $103,000. Oppenheimer Asset Management Inc. acquired a new position in shares of Qiagen N.V. during the first quarter worth about $114,000. Quadrant Capital Group LLC increased its position in shares of Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares during the period. Rehmann Capital Advisory Group acquired a new position in shares of Qiagen N.V. during the first quarter worth about $207,000. Finally, Prudential Financial Inc. acquired a new position in shares of Qiagen N.V. during the first quarter worth about $207,000. Hedge funds and other institutional investors own 61.03% of the company’s stock.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.